Show simple item record

dc.contributor.authorGriffin, Daniel J
dc.contributor.authorColey, Connor W
dc.contributor.authorFrank, Scott A
dc.contributor.authorHawkins, Joel M
dc.contributor.authorJensen, Klavs F
dc.date.accessioned2025-02-06T15:17:50Z
dc.date.available2025-02-06T15:17:50Z
dc.date.issued2023-11-17
dc.identifier.urihttps://hdl.handle.net/1721.1/158179
dc.description.abstractThe goals of this Perspective are threefold: (1) to inform a broad audience, including machine learning (ML) and artificial intelligence (AI) academics and professionals, about synthetic drug substance process development, (2) to break down the general synthetic drug substance process development task into more tractable subtasks, and (3) to highlight areas in which machine learning and artificial intelligence might be beneficially developed and applied. Application of machine learning and artificial intelligence to chemical synthesis of medicinal compounds has long been discussed and has resulted in the development of a number of computer-aided synthesis planning tools by both academic groups and commercial enterprises. The focus of these efforts has primarily centered on the task of retrosynthetic analysis, as seen from the perspective of a medicinal chemist. This has left significant unrealized opportunities in the application of machine learning and artificial intelligence to aid the process chemist or engineer in commercial drug substance process development.en_US
dc.language.isoen
dc.publisherAmerican Chemical Societyen_US
dc.relation.isversionof10.1021/acs.oprd.3c00229en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivativesen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourceAmerican Chemical Societyen_US
dc.titleOpportunities for Machine Learning and Artificial Intelligence to Advance Synthetic Drug Substance Process Developmenten_US
dc.typeArticleen_US
dc.identifier.citationGriffin, Daniel J, Coley, Connor W, Frank, Scott A, Hawkins, Joel M and Jensen, Klavs F. 2023. "Opportunities for Machine Learning and Artificial Intelligence to Advance Synthetic Drug Substance Process Development." Organic Process Research & Development, 27 (11).
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.relation.journalOrganic Process Research & Developmenten_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2025-02-05T21:39:55Z
dspace.orderedauthorsGriffin, DJ; Coley, CW; Frank, SA; Hawkins, JM; Jensen, KFen_US
dspace.date.submission2025-02-05T21:39:56Z
mit.journal.volume27en_US
mit.journal.issue11en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record